At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 255 enrolled
Drug / intervention
pregabalin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 9 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study Of Pregabalin (BID) In Subject With Posttraumatic Peripheral Neuropathic Pain
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Feb 15, 2006·Updated Feb 9, 2021
In Brief
A Phase 4 clinical trial evaluating pregabalin and Placebo for Neuralgia. Completed, enrolled 255 participants across 44 sites in 11 countries.
Detailed Summary
To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic pain
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia
CountriesBelgium, Canada, Denmark, Finland, Italy, Netherlands, Portugal, Romania, Sweden, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedFeb 2006
Primary CompletionMay 2008
TodayJul 2026
First PostedFeb 15, 2006
Enrollment StartJan 1, 2006
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.4 years ago
Interventions
pregabalindrug
pregabalin
Placebodrug
placebo